title: Effects of ouabain and flecainide on CO(2)-induced slowly adapting pulmonary stretch receptor inhibition in the rabbit.
abstract: The inhibitory effect of CO2 on slowly adapting pulmonary stretch receptors (SARs) was examined before and after administration of ouabain, a Na+-K+ ATPase inhibitor, and flecainide, a Na+ channel blocker. The experiments were performed in anesthetized, artificially ventilated rabbits after vagus nerve section. CO2 inhalation (maximal tracheal CO2 concentration ranging from 9.2 % to 10.4%) for about 60 sec decreased the receptor activity during both inflation and deflation. The magnitude of decreased SAR activity during deflation was greater than that seen during inflation. Administration of ouabain (25 microg/kg) initially stimulated SAR activities during inflation and deflation, and after 20 min, the SAR response was still kept excitatory in both inflation and deflation phases. Under these conditions, CO2 inhalation inhibited SAR activities during inflation and deflation. Flecainide treatment (3 mg/kg) that abolished veratridine (30 microg/kg)-induced SAR excitation had no significant effect on the inhibitory responses of SAR activity to CO2. These results suggest that the inhibitory effect of CO2 occurs when ouabain results in intracellular Na+ concentration ([Na+]i) increases in the SAR endings, and that CO2-induced SAR inhibition may not be related to the reduction of influx of Na+ through voltage-gated Na+ channels.
authors.affiliation: Department of Physiology, Nippon Dental University, School of Dentistry at Tokyo, Fujimi, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Matsumoto
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Tanimoto
authors.forename: C
authors.initials: C
authors.lastname: Saiki
authors.forename: M
authors.initials: M
authors.lastname: Takeda
mesh_terms: D000222:Adaptation, Physiological / Q000187:drug effects*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D005424:Flecainide / Q000494:pharmacology*; D008297:Male; D010042:Ouabain / Q000494:pharmacology*; D011661:Pulmonary Stretch Receptors / Q000187:drug effects* / Q000502:physiology; D012123:Pulmonary Ventilation / Q000187:drug effects / Q000502:physiology; D011817:Rabbits; D012121:Respiration, Artificial; D026941:Sodium Channel Blockers; D015222:Sodium Channels / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors / Q000378:metabolism; D013997:Time Factors; D014132:Trachea / Q000187:drug effects / Q000201:enzymology / Q000294:innervation / Q000378:metabolism; D014630:Vagus Nerve / Q000502:physiology / Q000601:surgery; D014701:Veratridine / Q000494:pharmacology
chemical_list: D026941:Sodium Channel Blockers; D015222:Sodium Channels; D002245:Carbon Dioxide; D010042:Ouabain; D014701:Veratridine; D000254:Sodium-Potassium-Exchanging ATPase; D005424:Flecainide